- Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther.
2017;16(11):2598-2608.
- White T, Szelinger S, LoBello J, et al. Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®. Oncotarget. 2021;12(8):726-739.
- Asmann YW, Parikh K, Bergsagel PL, et al. Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. NPJ Precis Oncol. 2021;5(1):22.
- Exact Sciences estimate is based on historical billing. This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid and commercial
insurance and includes the cost of both NGS and IHC components as most commonly ordered by providers. Patient cost-sharing amounts, including deductibles and copays
will vary by plan and coverage type. Only your patient’s insurer can confirm if and how the OncoExTra® test will be covered.
- As of February 14, 2024
- Genomic Health, Inc., an Exact Sciences company, is the billing entity for Oncotype® and OncoExTra® tests.
* De La O J, Flannery C, Deem A, Seerapu S, Basu G. Low Limit of Detection Increases Detection and Reporting of Actionable Genomic Alterations. Association for Molecular Pathology 2024 Annual Meeting Abstracts. J Mol Diagn 2024, 26: S1-S169. Abstract ST117.
‡ This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance for the Next Generation Sequencing (NGS) component only. Patient cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your insurer can confirm if and how each component of the OncoExTra® test will be covered. The NGS numbers cited are based on historical patient billing data from 01/02/2023 to 12/29/2023. Rates of coverage vary by state and region. Exceptions for coverage may apply. Additional IHC orders will likely require patient cost-sharing. Exact Sciences strongly encourages you to contact your insurer with questions about OncoExTra® test coverage.